OncoMatch/Clinical Trials/NCT06245746
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Is NCT06245746 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo) for acute myeloid leukemia.
Treatment: umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo) — The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytarabine or cytarabine-based consolidation therapy (cytarabine) — consolidation
are going to receive consolidation therapy (cytarabine or cytarabine-based combined regimen, the cycle of consolidation therapy is not limited)
Cannot have received: radiation therapy on sternum or pelvis
Previous radiation therapy performed on sternum or pelvis
Cannot have received: immunosuppressants
Continuous usage of immunosuppressants or received organ transplantation in the last 6 months
Cannot have received: clinical trial drugs
Participation in clinical trials of other drugs within 6 weeks before enrollment
Cannot have received: clinical stem cell or exosome research
Previous participation in clinical stem cell or exosome research
Cannot have received: agents inhibiting cell division (hydroxyurea, low-dose cytarabine, methotrexate)
Receive any agent concurrently with UCMSC-Exo infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc)
Lab requirements
Kidney function
serum creatinine of at most 1.5 times/upper limit of normal value
Liver function
alanine aminotransferase/aspartate aminotransferase of at most 2.5 times/upper limit of normal value and serum total bilirubin of at most 1.5 times/upper limit of normal value
Cardiac function
ejection fraction of left ventricular of at least 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify